Maxeon Solar Technologies 주식 (NASDAQ: MAXN)

Maxeon Solar Technologies (NASDAQ:MAXN) 주식

Maxeon Solar Technologies

Maxeon Solar Technologies Ltd is engaged in the manufacturing and marketing of premium solar technology. It owns and operates solar cell and panel manufacturing facilities located in Malaysia, Mexico, and the Philippines. The company's primary products are the Maxeon line of interdigitated back contact (IBC) solar cells and panels, and the Performance line (formerly, P-Series) of shingled solar cells and panels. the Maxeon line of solar panels are the highest-efficiency solar panels on the market with an aesthetically pleasing design, and the Performance line of solar panels offers a high-value and cost-effective solution. It is targeted at residential and small-scale commercial customers across the globe. The company derives its revenue from the United States, France, Italy, and others.

Analyst Color

Government

Large Cap

News

Downgrades

Price Target

Analyst Ratings

Movers

Trading Ideas

General

FSLR

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

SEDG

TPIC

최근 미국 대통령 선거 결과, 특히 공화당의 압승은 도널드 트럼프 대통령 당선인의 지도하에 재생 에너지의 미래에 대한 의문을 제기했다. 모건 스탠리의 보고서는 다양한 정책 시나리오에 따른 재생 에너지의 경제적 영향을 평가하고, 이것이 수익성에 미치는 영향을 분석한다.

트럼프의 당선, 경제적 도전으로 인해 재생 에너지 주식의 전망이 암울: 모건 스탠리

Maxeon Solar Technologies Ltd

For the second quarter of fiscal 2025, total revenues are expected to be between $675 million and $775 million, adjusted homebuilding gross margin is expected to be between 17.5% and 18.5%, adjusted income before income taxes is expected to be between $20 million and $30 million and adjusted EBITDA is expected to be between $50 million and $60 million.

Guidance

Hovnanian Enterprises Expects Q2 Revenue Of $675M-$775M Vs. $821.8M Est., Adj EBITDA Of $50M-$60M

Asset Sales

Sun Communities Entered Into Agreement To Sell 100% Interest Of Safe Harbor Marinas To Blackstone Infrastructure For $5.65B

Raymond James analyst Stephen Laws downgrades Arbor Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>) from Outperform to Market Perform.

Raymond James Downgrades Arbor Realty Trust to Market Perform

Citizens Capital Markets analyst David Turkaly reiterates Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) from Market Perform to Market Perform.

Reiteration

GMED

Citizens Capital Markets Reiterates Market Perform on Globus Medicalto Market Perform

Northland Capital Markets analyst Ted Jackson upgrades Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) from Market Perform to Outperform and maintains the price target from $100 to $100.

Upgrades

Northland Capital Markets Upgrades Toro to Outperform, Maintains Price Target to $100

On Monday, the FDA declined Invivyd, Inc.&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>)&nbsp;request to expand the existing emergency use authorization (EUA) for pre-exposure prophylaxis of COVID-19 EUA for Pemgarda (pemivibart) for mild-to-moderate COVID-19 in adults and adolescents who have moderate-to-<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43908842/fda-declined-invivyds-request-to-expand-existing-emergency-use-authorization-of-pemgarda-pemivibar" rel="noreferrer noopener">severe immune compromise</a>.
Existing Pemgarda emergency use for pre-exposure prophylaxis of COVID-19 in certain immunocompromised patients remains in effect.
The company said the COVID-19 treatment opportunity for pemivibart was not contemplated in existing financial guidance.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42920654/whats-going-on-with-covid-19-antibody-developer-invivyd-stock-on-friday" rel="noreferrer noopener">What&#8217;s Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?</a>
FDA&#8217;s reasoning appears to center on a belief that COVID-19 treatment immunobridging analyses for a monoclonal antibody (mAb) must meet a standard of superior antiviral activity rather than equivalent antiviral activity to past, highly effective, previously authorized and now inactive COVID-19 mAbs in a bridging analysis of sVNA1&nbsp;titer levels, otherwise the Agency is &#8220;unable to reasonably conclude that the known and potential benefits of pemivibart…outweigh the known and potential risks&#8221;
In the near term, Invivyd plans to share detailed data and regulatory correspondence regarding pemivibart, VYD2311, and the immunobridging of COVID-19 antibodies.
Earlier this month,&nbsp;Invivyd released new data from the <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43438525/invivyd-touts-encouraging-data-from-covid-19-antibody-trial-stock-jumps" rel="noreferrer noopener">ongoing Phase 1/2 trial of VYD2311</a>.
As of Day 65, serum concentrations remain high, potentially substantially increasing the observed half-life of VYD2311 relative to pemivibart, the company's&nbsp;monoclonal antibody&nbsp;medication authorized for the&nbsp;pre-exposure prophylaxis&nbsp;(prevention) of&nbsp;COVID‑19.
Price Action: IVVD stock is down 29.9% at $1.24&nbsp;during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/25/02/43909136/equitable-inks-reinsurance-deal-with-rga-and-plans-to-boost-stake-in-alliancebernstein-details" target="_blank" rel="noreferrer noopener">Equitable Inks Reinsurance Deal With RGA And Plans To Boost Stake In AllianceBernstein: Details</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

IVVD

FDA Rejects Invivyd's Request To Expand Emergency Authorization For Preventive COVID-19 Antibody For Immunocompromised Patients

Citizens Capital Markets analyst Constantine Davides maintains Evolent Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVH#NYSE">EVH</a>) with a Market Outperform and raises the price target from $12 to $13.

Citizens Capital Markets Maintains Market Outperform on Evolent Health, Raises Price Target to $13

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) just dropped a headline-grabbing $500 billion U.S. investment plan, promising factories, jobs, and <a href="https://www.benzinga.com/tech/25/02/43910982/apple-commits-500-billion-in-us-investment-for-ai-push-boost-us-manufacturing-tech">a whole lot of chipmaking</a>.
While the headlines sound impressive — investors want to know if the stock is ready to rally or fizzle out.
<h2 class="wp-block-heading">Bullish Momentum, But Cracks Are Showing</h2>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="629" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24073043/Screenshot-2025-02-24-at-6.00.26-PM.png" alt="" class="wp-image-795273" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24073043/Screenshot-2025-02-24-at-6.00.26-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/24073043/Screenshot-2025-02-24-at-6.00.26-PM-300x233.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent022425&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
From a technical perspective, Apple&#8217;s stock is flashing bullish signals across the board. Trading at $245.55, Apple stock sits comfortably above its five, 20, and 50-day exponential moving averages (EMAs), typically a strong indicator of upward momentum. The eight-day simple moving average (SMA) stands at $242.04, while the 20-day sits at $236.10, both signaling continued bullishness.
The Moving Average Convergence Divergence (MACD) indicator at 2.22 reinforces the positive trend, while the Relative Strength Index (RSI) of 61.17 suggests the stock isn't overbought just yet. 
And with the 200-day SMA trailing far behind at $224.39, Apple's current price remains firmly in bullish territory.
Read Also: <a href="https://www.benzinga.com/tech/25/02/43906680/apples-m4-macbook-air-set-for-march-debut-says-top-analyst-new-13-inch-and-15-inch-models-reportedly-incoming">Apple&#8217;s M4 MacBook Air Set For March Debut, Says Top Analyst — New 13-Inch And 15-Inch Models Reportedly Incoming</a>
<h2 class="wp-block-heading">Selling Pressure Clouds The Picture</h2>
But here's the catch: despite the technical strength, Apple&#8217;s stock is facing noticeable selling pressure. This often hints at a potential cooldown, especially after an extended rally. 
While Apple&#8217;s massive investment plan may provide fundamental support, technical traders will be watching closely for signs of a reversal.
<h2 class="wp-block-heading">Investor Takeaway</h2>
Apple&#8217;s <a href="https://www.apple.com/newsroom/2025/02/apple-will-spend-more-than-500-billion-usd-in-the-us-over-the-next-four-years/">$500 billion splash</a> might make headlines, but the real story lies in the charts. The stock is undeniably bullish for now, but with selling pressure building, chasing the rally without a tight stop could get risky. 
Keep an eye on those moving averages—if Apple stock slips below the 20-day SMA, the bears might finally get their turn.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/02/43906541/alibaba-to-invest-a-massive-53-billion-in-ai-infrastructure-taking-on-trumps-stargate-ai-plan">Alibaba To Invest A Massive $53 Billion In AI Infrastructure, Taking On Trump&#8217;s Stargate AI Plan</a></li>
</ul>
Image: Shutterstock

Technicals

Tech

AAPL

Apple Makes $500 Billion Bet: Is AAPL Stock Ready To Shine Or Stumble?

SBET

SharpLink Gaming Acquires 10% Equity Stake In Armchair Enterprises For $500,000 And Right of First Refusal To Acquire Controlling Interest

Lake Street analyst Brooks O'Neil initiates coverage on Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) with a Buy rating and announces Price Target of $30.

Initiation

BBNX

Lake Street Initiates Coverage On Beta Bionics with Buy Rating, Announces Price Target of $30

Hovnanian Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOV#NYSE">HOV</a>) reported quarterly earnings of $3.58 per share. This is a 23.02 percent increase over earnings of $2.91 per share from the same period last year. The company reported quarterly sales of $673.62 million which missed the analyst consensus estimate of $705.80 million by 4.56 percent. This is a 13.37 percent increase over sales of $594.20 million the same period last year.

Earnings

Earnings Misses

Hovnanian Enterprises Q1 2025 GAAP EPS $3.58 Up From $2.91 YoY, Sales $673.62M Miss $705.80M Estimate

<ul>
<li>TSLA</li>
<li>NVDA</li>
<li>LUNR</li>
<li>PLTR</li>
<li>SMCI</li>
<li>BABA</li>
<li>GOOGL</li>
<li>NBIS</li>
<li>AAPL</li>
<li>HOOD</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

BABA

GOOGL

HOOD

LUNR

NBIS

NVDA

PLTR

SMCI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of February 24, 2025 (Via Swaggy Stocks)

Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and methylation, as well as a new multimodal data analysis platform
Built on Illumina's powerful sequencers, new, disruptive omics solutions surpass industry standards for quality, scale, accuracy, and replicability
SAN DIEGO, Feb. 24, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) has unveiled a series of roadmap innovations, establishing the industry's largest portfolio of omics solutions and sequencing applications. The solutions – spanning genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, epigenetics, and data analytics software – will enable researchers to derive breakthrough insights around the drivers of disease. The new omics solutions surpass industry standards for scale, accuracy, and reliability because they are built on Illumina's powerful sequencers, known for unmatched quality, consistency, and accuracy. The expanded multiomics portfolio will be presented today at the Advances in Genome Biology and Technology (AGBT)&nbsp;General Meeting.

ILMN

Illumina Unveils Largest Omics Solutions Portfolio Including Genomics, Spatial, Single Cell, CRISPR Technologies; Introduces Multimodal Data Analysis Platform

In the current market session, Enterprise Prods Partners Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPD#NYSE">EPD</a>) share price is at $33.50, after a 0.48% spike. Moreover, over the past month, the stock fell by 1.10%, but in the past year, went up by 20.75%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1740406519_0.png" alt="Past Year Chart" />

<h3>Enterprise Prods Partners P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 29.51 in the Oil, Gas &amp; Consumable Fuels industry, Enterprise Prods Partners Inc. has a lower P/E ratio of 12.39. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1740406519_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

A Look Into Enterprise Prods Partners Inc's Price Over Earnings

<a href="https://www.benzinga.com/startups/25/02/43451833/warren-buffetts-1m-bet-why-simple-index-funds-crushed-hedge-funds-by-7-1-to-2-2-over-a-decade">Warren Buffett's</a> Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>, BRK.B))&nbsp; made some big moves in the last quarter, shifting its investments in response to changing market conditions.&nbsp;
<a href="https://13f.info/13f/000095012325002701-berkshire-hathaway-inc-q4-2024">A regulatory filing</a> released on Feb. 14, showed that Berkshire slashed its stake in Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), cutting its shares from over 1 billion to about 680 million by the end of last year. The drop reduced Berkshire's ownership from over 13% to 11%, bringing the value of the investment from about $41 billion to under $30 billion.
Don't Miss:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
</ul>
<h2 class="wp-block-heading">Strategic Portfolio Adjustments</h2>
Beyond Bank of America, Berkshire adjusted several other financial holdings. According to the filing, the firm sold 74% of its Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) stake, 18% of its Capital One (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) position, and 54% of its shares in Nu Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>).&nbsp;
It also trimmed investments in Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>), Louisiana-Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>), and T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>). The changes indicate a move away from financial stocks and select industries.
At the same time, Berkshire made a notable addition, buying a $1.2 billion stake in Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>), the company behind popular beers like Corona and Modelo. As per market trends, consumer staples tend to hold up well in uncertain economic times, making this a strategic shift toward more stable investments.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
Berkshire also increased its holdings in companies tied to steady consumer demand. Its stake in Domino's Pizza (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) grew by 86%, and its investment in Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) jumped by 48%.&nbsp;
These moves suggest confidence in businesses that remain relevant regardless of market conditions—whether people are tightening their budgets or not, they still order pizza and maintain their pools.
Not all holdings made the cut. Berkshire fully exited Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) despite only acquiring shares in the second quarter of 2024.&nbsp;
See Also: Many don&#8217;t know there are tax benefits when buying a unit as an investment —<a href="https://www.benzinga.com/money/casa-shares"> Here&#8217;s how to invest in real estate by mirroring BlackRock's big move</a>
It also sold off its positions in two major exchange-traded funds (ETFs) that track the S&amp;P 500—SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>). This suggests a more targeted approach rather than following the broader market.
Berkshire's cash pile has reached record levels. According to its <a href="https://www.berkshirehathaway.com/qtrly/3rdqtr24.pdf">financial reports</a>, the company sold about $133 billion worth of stocks in the first nine months of 2024 while buying less than $6 billion.&nbsp;
Share buybacks also slowed, with under $3 billion spent compared to nearly $70 billion over the previous four years, <a href="https://africa.businessinsider.com/news/warren-buffett-dumped-stocks-built-a-dollar300-billion-cash-pile-and-updated-his/pgecrnn">according to Business Insider</a>.&nbsp; These moves helped Berkshire's cash reserves soar past $300 billion for the first time, nearly doubling from $168 billion at the start of the year, the report added.&nbsp;
Read Next:
<ul>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

CHTR

POOL

TMUS

ULTA

Berkshire Hathaway Dumps Ulta Beauty, Citi, And ETFs – But Buffett Just Bet $1.2 Billion On This Alcohol Giant

Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) has outperformed the market over the past 10 years by 5.34% on an annualized basis producing an average annual return of 16.35%. Currently, Autodesk has a market capitalization of $61.65 billion. 
Buying $1000 In ADSK: If an investor had bought $1000 of ADSK stock 10 years ago, it would be worth $4,453.12 today based on a price of $286.06 for ADSK at the time of writing.
<h3>Autodesk's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740406509_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADSK

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

MSFT

Microsoft To Jefferies Says 'Strongly Refute' Any Change To Data Center Strategy

Barclays analyst John Coffey maintains Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Overweight and lowers the price target from $120 to $117.

FOUR

Barclays Maintains Overweight on Shift4 Payments, Lowers Price Target to $117

WRAP

Wrap Technologies Has Completed The Acquisition Of W1 Global; Terms Not Disclosed

On Monday, Glaukos Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) received the &#8220;Day 74&#8221; notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-gen corneal cross-linking iLink therapy for keratoconus, a sight-threatening corneal disease, is sufficiently complete to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43908675/glaukos-announces-fda-acceptance-of-nda-submission-for-epioxa" rel="noreferrer noopener">permit a substantive review</a>.
The Prescription Drug User Fee Act goal date for the completion of the FDA&#8217;s review of the Epioxa NDA is set for Oct. 20, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43883818/glaukos-delivers-mixed-q4-results-analyst-sees-growing-investor-interest-during-transition" rel="noreferrer noopener">Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition</a>
&#8220;The acceptance of the Epioxa NDA represents another important step in being able to provide keratoconus patients and the ophthalmic community with the first FDA-approved, non-invasive corneal cross-linking drug therapy that does not require removal of the corneal epithelium, the outermost layer of the front of the eye,&#8221; said Glaukos CEO Thomas Burns.
The NDA submission includes data from two Phase 3 pivotal Epioxa trials, which achieved the pre-specified primary efficacy endpoints and demonstrated favorable tolerability and safety profiles.
Glaukos&#8217; corneal cross-linking iLink therapies use proprietary, bio-activated drug formulations designed to strengthen corneal tissue and halt the progression of keratoconus.
Glaukos&#8217; first-generation iLink therapy, known as Photrexa, or&nbsp;Epi-off, is the first and only FDA-approved therapy that has been shown to slow or halt disease progression.
Epioxa utilizes a proprietary, novel drug formulation designed to penetrate the epithelial layer of the cornea, a stronger UV-A irradiation protocol, and supplemental oxygen to enhance cross-linking.
Price Action: GKOS stock is up 25% at $157.36&nbsp;during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43890152/insulets-strong-q4-highlights-surging-omnipod-demand-and-growth-potential-analyst-sees-continued-growth-in-2025" target="_blank" rel="noreferrer noopener">Insulet&#8217;s Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst</a></li>
</ul>
Image: Shutterstock

GKOS

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Commodities

Press Releases

Cypress Creek Renewables Selects Maxeon Solar Solutions for Major Utility Scale Projects

Stock Split

Maxeon Receives Nasdaq Notification and is Proceeding with Approved Reverse Stock Split

Pomerantz Law Firm Announces the Filing of a Class Action Against Maxeon Solar Technologies, Ltd. - MAXN

Maxeon Announces CEO Leadership Transition

Maxeon Provides Update on CBP Detention of its Solar Panels

Maxeon Announces Restructuring of Business Portfolio

Maxeon Solar Technologies Announces Third Quarter 2024 Financial Results

Maxeon and Tongwei Solar Announce Settlement Agreement Resolving Patent Infringement Lawsuit

Ascent Solar Technologies, Inc - Common Stock

Ascent Solar Technologies

Datavault AI

GCT Semiconductor Holding, Inc. Common Stock

GCT Semiconductor Hldgs

GSI Technology

Intchains Group Limited - American Depositary Shares

Intchains Gr

Kopin

SEALSQ

SemiLEDs

Mobix Labs

Everspin Technologies, Inc. - Common Stock

Everspin Technologies

Magnachip Semiconductor Corporation Common Stock

MagnaChip Semiconductor

Nano Labs

Peraso

Pixelworks

QuickLogic

Semilux International Ltd. - Ordinary Shares

Semilux International

SmartKem

Sequans Communications S.A. American Depositary Shares (each representing ten (10) Ordinary Shares)

Comments

Maxeon Solar Technologies

뉴스

파트너 / 기고자

벤징가 글로벌